Dynavax Deferred Long Term Liab from 2010 to 2025
| DVAX Stock | USD 13.68 0.10 0.74% |
Deferred Long Term Liabilities | First Reported 2011-06-30 | Previous Quarter 68 M | Current Value 349.9 M | Quarterly Volatility 62.7 M |
Check Dynavax Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dynavax Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.5 M, Interest Expense of 4.2 M or Other Operating Expenses of 295.4 M, as well as many indicators such as Price To Sales Ratio of 5.69, Dividend Yield of 0.0 or PTB Ratio of 4.39. Dynavax financial statements analysis is a perfect complement when working with Dynavax Technologies Valuation or Volatility modules.
Dynavax | Deferred Long Term Liab |
Latest Dynavax Technologies' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Dynavax Technologies over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Dynavax Technologies' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dynavax Technologies' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Dynavax Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 184,382,274 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 102.04 | |
| Mean Deviation | 181,116,274 | |
| Median | 349,864,000 | |
| Standard Deviation | 188,147,404 | |
| Sample Variance | 35399.4T | |
| Range | 422.5M | |
| R-Value | 0.89 | |
| Mean Square Error | 8011T | |
| R-Squared | 0.79 | |
| Slope | 35,098,095 | |
| Total Sum of Squares | 530991.7T |
Dynavax Deferred Long Term Liab History
About Dynavax Technologies Financial Statements
Dynavax Technologies investors use historical fundamental indicators, such as Dynavax Technologies' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Dynavax Technologies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 402.3 M | 422.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.